Nautilus Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 69.37K shares, a 282.44% increase year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 600.87K shares, a 1320.73% increase year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 51.65K shares, a 87.77% decline year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 112.08K shares, a 85.81% decline from fiscal 2024.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 790.11K shares, a 1014.95% increase from fiscal 2023.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 70.86K shares, a 84.70% decline from fiscal 2022.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 463.21K shares, a 69.24% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 69.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | 721.90K shares derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | 600.87K shares 10-Q · filed 2026-04-28 | 670.66K shares derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | 51.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 112.08K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | 482.73K shares derived: sum of 4 quarters · filed 2025-10-28 |
| 2025-06-30 | 18.14K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | 636.29K shares derived: sum of 4 quarters · filed 2025-07-31 |
| 2025-03-31 | 42.29K shares 10-Q · filed 2025-04-29 | 635.99K shares derived: sum of 4 quarters · filed 2025-04-29 |
| 2024-12-31 | 422.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 790.11K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 153.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | 422.90K shares derived: sum of 4 quarters · filed 2024-10-29 |
| 2024-06-30 | 17.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | 279.21K shares derived: sum of 4 quarters · filed 2024-07-30 |
| 2024-03-31 | 196.41K shares 10-Q · filed 2024-04-30 | 266.37K shares derived: sum of 4 quarters · filed 2024-04-30 |
| 2023-12-31 | 55.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 70.86K shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 9.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | 106.90K shares derived: sum of 4 quarters · filed 2023-10-31 |
| 2023-06-30 | 5.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 257.81K shares derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | 907.00 shares 10-Q · filed 2023-05-02 | 310.54K shares derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-12-31 | 91.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 463.21K shares 10-K · filed 2023-02-23 |
| 2022-09-30 | 160.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 508.40K shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 57.74K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | 420.00K shares derived: sum of 4 quarters · filed 2022-08-02 |
| 2022-03-31 | 153.57K shares 10-Q · filed 2022-05-03 | |
| 2021-12-31 | 136.31K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 273.70K shares 10-K · filed 2022-02-24 |
| 2021-09-30 | 72.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | |
| 2020-12-31 | 137.29K shares 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |